Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Gain Therapeutics, Inc. develops allosteric small molecule therapies for neurodegenerative and other difficult-to-treat diseases. The company’s lead candidate, GT-02287, is being developed for Parkinson’s disease with or without a GBA1 mutation and is designed as a brain-penetrant allosteric enzyme modulator of glucocerebrosidase, or GCase.
Recurring news for GANX includes financial results, corporate updates, clinical and biomarker data for GT-02287, FDA and IND-related communications, and scientific presentations at Parkinson’s and neurodegeneration conferences. Company updates also cover the Magellan™ drug discovery platform, preclinical GCase modulator programs such as GT-04686, and pipeline areas including lysosomal storage disorders, metabolic diseases and solid tumors.
Gain Therapeutics (Nasdaq: GANX) announced that CEO Eric Richman will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit from September 20-23, 2021. The presentation is scheduled for September 22 from 1:15 to 1:55 p.m. ET. Investors can participate via webcast and one-on-one meetings. Gain Therapeutics focuses on optimizing allosteric binding sites in treatments for neurodegenerative diseases.
Gain Therapeutics, focused on neurodegenerative diseases, announced a presentation by Dr. Manolo Bellotto on their allosteric regulators for GM1 Gangliosidosis and Morquio B Disease. The presentation will take place on September 14, 2021, at 2:00 PM PT/5:00 PM ET during the GM1 Virtual Community Conference. These diseases are linked to mutations in the GLB1 gene, leading to toxic substrate accumulation. Gain's STARs aim to potentially treat neurological symptoms, marking a significant advancement in the field.
Gain Therapeutics (Nasdaq: GANX) reported positive topline data from its study on two STAR compounds, GT-02287 and GT-02329, aimed at treating Gaucher Disease and GBA1 Parkinson’s Disease. Conducted at the University of Maryland, the study showed increased GCase protein levels, enhanced enzymatic activity, and decreased α-synuclein in neurons. The company plans to present comprehensive data at an upcoming Michael J. Fox Foundation webinar and initiate IND-enabling studies in Q4 2021, further supporting its Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) platform.
Gain Therapeutics (GANX) announced positive topline data from a study on its compounds GT-02287 and GT-02329 for treating Gaucher and GBA1 Parkinson's Disease. The study showed increased GCase protein levels and activity, along with a decrease in toxic α-synuclein levels. Conducted in collaboration with the University of Maryland School of Medicine, findings will be presented in a webinar organized by the Michael J. Fox Foundation. The company plans to initiate IND-enabling studies for these treatments in Q4 2021.
Gain Therapeutics (Nasdaq: GANX), a biotechnology company specializing in neurodegenerative and lysosomal storage disorders, announced that CEO Eric Richman will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. An on-demand presentation will be available starting September 13, 7:00 am ET for 90 days. Richman and CFO Salvatore Calabrese are available for virtual 1x1 meetings during the conference. Gain is focused on innovative drug discovery and is supported by organizations like The Michael J. Fox Foundation.
Gain Therapeutics, Inc. (GANX) reported a cash position of $43.16 million as of June 30, 2021, significantly up from $7.49 million at the end of 2020. The company continues to advance its developmental programs while expanding its intellectual property portfolio, including two new patents targeting misfolded proteins linked to neurodegenerative diseases. Revenues for Q2 2021 reached $89,000, up from $7,000 in Q2 2020, primarily due to collaboration with Zentalis Pharmaceuticals. However, net losses increased to $3.56 million compared to $543,000 a year earlier.
Gain Therapeutics (Nasdaq: GANX) announced that CEO Eric Richman will present a corporate overview at the BTIG Virtual Biotechnology Conference on August 9-10, 2021. His presentation is scheduled for 11:30 to 11:55 a.m. ET on August 9. Gain Therapeutics specializes in drug discovery targeting protein misfolding associated with neurodegenerative diseases and lysosomal storage disorders. The event expects participation from over 120 management teams and offers thematic panels and one-on-one meetings.
Gain Therapeutics (Nasdaq: GANX) announced the issuance of two PCT patents on June 10, 2021, targeting compounds for misfolded enzymes associated with neurodegenerative and lysosomal storage diseases. The patents include PCT/IB2020/061158, which addresses diseases like Gaucher Disease and Parkinson’s Disease, and PCT/IB2020/061156, focused on conditions linked to GALC alterations. CEO Eric Richman emphasized this as a significant milestone for developing new therapies for these challenging diseases, reinforcing the company's intellectual property and commitment to innovation.
Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology firm, will present a corporate overview at the Jefferies Virtual Healthcare Conference from June 1 to June 4, 2021. CEO Eric Richman is set to speak on June 1 at 3:00 PM ET. The session will be accessible via webcast and will be available for replay on the company's website for 30 days post-conference. This annual conference gathers over 400 healthcare companies and 3,000 investors to discuss investment opportunities and trends in healthcare.
Gain Therapeutics, Inc. (Nasdaq: GANX) announced that CEO Eric Richman will present a corporate overview at the 2021 RBC Capital Markets Global Healthcare Virtual Conference on May 19 at 9:10 a.m. ET and at the Oppenheimer Rare & Orphan Disease Summit on May 21 at 8:15 a.m. ET. Both presentations will highlight Gain's innovative drug discovery approach using its SEE-Tx™ platform to target allosteric binding sites, addressing challenging disorders linked to protein misfolding. Webcast links for the events are available on the company’s website.